Introduction {#s1}
============

Cluster of differentiation 26 (CD26) is a multifunctional type II transmembrane serine peptidase which is present at low density on resting T lymphocytes and is up-regulated upon T lymphocyte activation. CD26 has an extracellular domain with DPP4 (dipeptidyl peptidase IV) enzymatic activity and a short cytoplasmic domain ([@B1]). A truncated form (sCD26/DPP4) is also present in serum and other body fluids ([@B2]). CD26/DPP4 exerts its immune-mediated and non-immune-mediated activities via various mechanisms such as its role in T lymphocyte activation and as a costimulatory interacting protein, which results in enhanced T cell effector functions; its role as a proteolytic enzyme and signal transduction mediator; as well as its role in adhesion and cell motility. Moreover, CD26/DPP4 appears to have a role in tumor biology, with its expression levels being associated with cancer progression and tumor malignant behavior ([@B1]--[@B5]).

Inhibition of DPP4 also prevents inactivation of glucagon like peptide-1 which in turn leads to the secretion of insulin and better glycemic control. As a result of this mechanism of action, DPP4 inhibitors (DPP4i) are approved and are used in diabetes mellitus type 2 as monotherapy as well as in combination with metformin. Several previous studies have also examined the relationship between new cancer initiation and the use of DPP4i, but no consistent relationships have been found. A large meta-analysis of 72 trials and a randomized controlled trial which specifically examined new cancer as a primary outcome did not show any significant association between use of DPP4i and cancer initiation ([@B6], [@B7]).

The role of CD26/DPP4 in prostate cancer is not yet well-understood. *In-vitro* studies showed that the blockage of CD26 in 1-LN tumor cell lines led to a decrease in tumor cell invasiveness ([@B8]). Another study using prostate cancer xenograft model showed that the DPP4 gene was down-regulated during the progression to castration-resistant prostate cancer, suggesting its tumor suppressive property ([@B9]). However, no studies have evaluated the clinical outcome of using DPP4i in prostate cancer patients. Similarly, the role of CD26/DPP4 in breast cancer remains poorly understood. *In-vitro* studies demonstrated thatinhibition of CD26/DPP4 stimulated breast cancer metastasis, likely via induction of CXCL12/CXCR4 ([@B10]), while others reported inhibition of CD26/DPP4 led to the suppression of breast cancer tumor growth ([@B11]). To evaluate the role of CD26/DPP4 inhibition in clinical setting, we conducted a retrospective analysis of patients with advanced airway and colorectal cancers with diabetes who were taking DPP4i ([@B12]). The study showed significant advantage in progression-free survival and a positive trend in overall survival (OS); however, OS did not reach the level of statistical significance likely due to small sample size ([@B12]). To further clarify the role of DPP4i, we conducted a SEER (Surveillance Epidemiology and Endpoint Research)-Medicare analysis of colorectal cancer and lung cancer patients, which also showed a similar trend toward beneficial effects associated with CD26/DPP4 inhibition ([@B13]). Apart from colorectal and lung cancer, CD26/DPP4 protein is well-expressed in prostate cancer cells, while its expression in pancreatic or breast cancer cells is relatively lower ([@B1], [@B2], [@B14]). In this present work, we aim to assess the impact of CD26/DPP4 inhibition in patients with prostate, pancreatic and breast cancerthrough the use of a national database.

Methods {#s2}
=======

We utilized the SEER-Medicare database for our study. SEER database represents \~34% of the U.S. population and is maintained by the National Cancer Institute ([www.seer.cancer.gov](http://www.seer.cancer.gov)) of the National Institutes of Health ([@B15]). The Medicare database is maintained by the Centers for Medicare and Medicaid Services for eligible US residents, and it comprise of over 97% of the US population aged 65 years or older. The database provides individual patient level demographic and survival data from the SEER cancer registry in conjunction with comprehensive therapeutic information from the Medicare program ([@B16]).

Cohort Selection
----------------

By using International Classification of Diseases for Oncology, third edition (ICD-O-3) codes, we identify patients who were diagnosed with prostate cancer, or pancreatic cancer, or breast cancer and diabetes mellitus type 2 between 2007 and 2015. Patients were older than 65 years as the data source is SEER-Medicare. The study samples were restricted to those with continuous Medicare Part A and Part B insurance coverage and no HMO coverage 12 months before and 12 months after a cancer diagnosis or until death. [Figure 1](#F1){ref-type="fig"} shows the flowchart of patient selection with the detailed criteria used. By using generic name and National Drug Codes in SEER-Medicare Part D file, we identified use of DPP4i in our patient cohort. DPP4i such as, alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin were selected. Similarly, use of metformin was identified. [Table 1](#T1){ref-type="table"} shows characteristics of included patients. We used ICD (ninth revision) procedure codes, level II Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes in the Medicare claims to identify treatment rendered within 1 year of cancer diagnosis. We used the modified algorithm proposed by Klabunde et al. to calculate the Charlson Comorbidity Index ([@B17], [@B18]).

![Criteria used and flow chart of patient selection with prostate, pancreas, or breast cancer.](fonc-10-00405-g0001){#F1}

###### 

Baseline Characteristics of Study Cohort by DDP4 inhibition.

                                        **DDP4**                         
  ---------------------------- -------- ---------- ------ ------- ------ ----------
  **Demographics**                                                       
  Year of diagnosis                                                      \<0.0001
     2007                      2,161    2,127      6.3    34      1.1    
     2008                      3,713    3,544      10.6   169     5.2    
     2009                      3,891    3,700      11.0   191     5.9    
     2010                      3,844    3,592      10.7   252     7.8    
     2011                      4,147    3,795      11.3   352     10.9   
     2012                      4,245    3,771      11.2   474     14.7   
     2013                      4,737    4,179      12.5   558     17.3   
     2014                      4,935    4,326      12.9   609     18.9   
     2015                      5,101    4,520      13.5   581     18.0   
  Age group                                                              0.0873
     65--69                    9,246    8,445      25.2   801     24.9   
     70--74                    10,848   9,861      29.4   987     30.7   
     75--79                    8,146    7,409      22.1   737     22.9   
     80+                       8,534    7,839      23.4   695     21.6   
  Sex                                                                    0.9957
     Male                      17,692   16,143     48.1   1,549   48.1   
     Female                    19,082   17,411     51.9   1,671   51.9   
  Race/ethnicity                                                         \<0.0001
     Non-hispanic white        24,795   22,733     67.8   2,062   64.0   
     Non-hispanic black        4,937    4,564      13.6   373     11.6   
     Hispanic                  2,757    2,412      7.2    345     10.7   
     Others                    4,285    3,845      11.5   440     13.7   
  Marital status                                                         0.1466
     Single                    6,855    6,279      18.7   576     17.9   
     Married                   17,389   15,814     47.1   1,575   48.9   
     Other                     12,530   11,461     34.2   1,069   33.2   
  Census poverty                                                         0.3801
     0-- \<5% poverty          7,393    6,712      20.0   681     21.1   
     5-- \<10%                 9,038    8,253      24.6   785     24.4   
     10--20%                   10,721   9,789      29.2   932     28.9   
     20--100%                  9,203    8,424      25.1   779     24.2   
     Unknown                   419      376        1.1    43      1.3    
  Census region                                                          \<0.0001
     West                      14,407   13,098     39.1   1,309   40.7   
     Northeast                 8,472    7,588      22.6   884     27.5   
     Midwest                   4,653    4,402      13.1   251     7.8    
     South                     9,224    8,450      25.2   774     24.1   
  Rural/urban status                                                     \<0.0001
     Urban area                32,155   29,253     87.2   2,902   90.1   
     Rural area                4,619    4,301      12.8   318     9.9    
  Charlson comorbidity index                                             \<0.0001
     0                         5,075    4,999      14.9   76      2.4    
     1                         14,636   13,351     39.8   1,285   39.9   
     2                         7,765    6,978      20.8   787     24.4   
     3+                        9,298    8,226      24.5   1072    33.3   
  Cancer type                                                            \<0.0001
     Breast                    16,085   14,777     44.0   1,308   40.6   
     Prostate                  15,330   14,096     42.0   1,234   38.3   
     Pancreas                  5,359    4,681      14.0   678     21.1   
  Stage                                                                  \<0.0001
     I                         6,781    6,188      18.4   593     18.4   
     II                        17,365   15,957     47.6   1,408   43.7   
     III                       2,123    1,918      5.7    205     6.4    
     IV                        5,019    4,463      13.3   556     17.3   
     Unknown                   5,486    5,028      15.0   458     14.2   
  Surgery                                                                \<0.0001
     No                        19,502   17,701     52.8   1,801   55.9   
     Yes                       17,272   15,853     47.2   1,419   44.1   
  Chemotherapy                                                           0.0008
     No                        24,575   22,508     67.1   2,067   64.2   
     Yes                       12,199   11,046     32.9   1,153   35.8   
  Radiotherapy                                                           0.0015
     No                        22,654   20,587     61.4   2,067   64.2   
     Yes                       14,120   12,967     38.6   1,153   35.8   
  Insulin                                                                \<0.0001
     No                        29,978   27,552     82.1   2,426   75.3   
     Yes                       6,796    6,002      17.9   794     24.7   
  Sulfonylurea                                                           \<0.0001
     No                        27,032   25,291     75.4   1,741   54.1   
     Yes                       9,742    8,263      24.6   1,479   45.9   

*DPP4, dipeptidyl peptidase*.

Statistical Analysis
--------------------

Metformin is commonly used for the management of DM-II. To evaluate the impact of DPP4i or metformin independently and in combination, patients were classified into four groups based on the use of DPP4i and metformin: (1) not on either agent (reference group), this group included patients that were on anti-diabetic agents other than metformin or DPP4i (2) metformin only, (3) DPP4i only, and (4) DPP4i along with metformin (combination group). Cox Proportional Hazards survival model was used to assess the overall survival (OS) of these groups, controlling for patients demographic and clinical characteristics. In subgroup analysis, we compared patients on DPP4i only against the reference group. Bivariate analyses compared baseline characteristics between patients taking DPP4i and not, using Pearson chi-square tests. The OS time was defined as from the date of cancer diagnosis until the date of death or loss of follow-up. Statistical significance was defined as a *P* \< 0.05. All analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, USA). The University of Florida institutional review board approval was obtained.

Results {#s3}
=======

We identified 16,085 breast cancer patients that met our inclusion criteria. [Table 1](#T1){ref-type="table"} shows the characteristics of selected patients. A total of 9,670 (60.11%) patients were not on metformin or DPP4i (reference group), while 5,107 (31.75%) patients were on metformin, 497 (3.08%) patients were on DPP4i, and 811 (5.04%) patients were on the metformin and DPP4i combination. As shown in [Figure 2A](#F2){ref-type="fig"}, the patients treated with metformin showed significant OS benefit with HR 0.79 (95% CI: 0.74--0.84), *P* \< 0.001 when compared to the reference group. Similarly, patients on metformin and DPP4i combination also showed a significant survival benefit with HR 0.73 (95% CI: 0.62--0.85), *P* \< 0.001 when compared to the reference group. However, survival did not favor the patients who were only on DPP4i with HR 1.07 (95% CI: 0.93--1.25, *P* = 0.33).

![Forest plot with hazard ratio showing survival analysis of breast cancer **(A)**, prostate cancer **(B)**, and pancreatic cancer **(C)** patients.](fonc-10-00405-g0002){#F2}

We identified 15,330 patients with prostate cancer who met our inclusion criteria. [Table 1](#T1){ref-type="table"} shows the characteristics of selected patients. A total of 8,911 (58.12%) patients were not on metformin or DPP4i (reference group), while 5,185 (33.82%) patients were on metformin, 414 (2.7%) patients were on DPP4i, and 820 (5.34%) patients were on the metformin and DPP4i combination. The group who was on metformin showed significant OS benefit with HR 0.87 (95% CI: 0.81--0.93), *P* \< 0.0001 when compared to the reference group. Similarly, patients on DPP4i also showed a significant survival benefit with HR 0.77 (95% CI: 0.64--0.93), *P* = 0.005 when compared to the reference group. Patients who were on a combination of metformin and DPP4i also showed survival advantage compared to the reference group HR 0.80 (95% CI: 0.68--0.94), *P* = 0.007 ([Figure 2B](#F2){ref-type="fig"}). For subgroup analyses, we only compared patients on DPP4i against reference group, to avoid confounding by metformin. It demonstrated the trend toward a beneficial effect of DPP4i, irrespective of stage (stage I, NR; stage II, HR 0.81; stage III, NR; stage IV, 0.76), treatments with chemotherapy (HR 0.83 with chemotherapy and HR 0.70 without chemotherapy), androgen-deprivation therapy (ADT) (HR 0.87 with ADT and HR 0.71 without ADT), prostatectomy (HR 0.50 with prostatectomy and HR 0.77 with no prostatectomy), or radiation (HR 0.89 with radiation therapyand HR 0.64 without radiationtherapy). However, statistical significance was not reached for the majority of them likely due to low sample size ([Figure 3](#F3){ref-type="fig"}).

![Forest plot with hazard ratio showing survival analysis of various subgroups within prostate cancer patients.](fonc-10-00405-g0003){#F3}

We identified 5,359 patients with pancreatic cancer who met our inclusion criteria. [Table 1](#T1){ref-type="table"} shows the characteristics of selected patients. A total of 2,734 (51%) patients were not on metformin or DPP4i (reference group), while 1,947 (36.33%) patients were on metformin, 241 (4.5%) patients were on DPP4i, and 437 (8.15%) patients were on metformin and DPP4i combination. As shown in [Figure 2C](#F2){ref-type="fig"}, none of these groups showed any beneficial effects on OS when compared to the reference group. Subgroup analysis was not performed as DPP4i did not show any beneficial effect in this group of patients.

Discussion {#s4}
==========

To the best of our knowledge, this is the first review of a large national database looking into the impact of DPP4i on the survival of prostate, pancreatic and breast cancer patients.

By using the SEER-Medicare database, we showed that the prostate cancer patients who were on DPP4i had better survival compared to those who were not treated with DPP4i. The survival advantage shown in patients with prostate cancer taking DPP4 inhibitors only (HR 0.77; 95% CI: 0.64--0.93; *P* = 0.005) shows the benefit independent of metformin. However, the survival advantage of DPP4i was not evident in pancreatic cancer and breast cancer patients. We believe that this pattern may likely be at least partly due to the expression profile of CD26/DPP4. Protein Atlas of immunohistochemistry data by antibody staining of various normal as well as cancerous human cells showed that several prostate cancers and a few renal cell carcinomas displayed moderate to strong membranous or cytoplasmic positivity to antibody to CD26/DPP4, while most other cancers including pancreatic and breast did not ([@B14]). Moreover, CD26/DPP4 biochemical activity was found to be twice as high in prostate cancer compared to benign prostate hyperplasia tissues ([@B19]), which could be a responsible factor for the growth of prostate cancer cells. Furthermore, in an analysis of prostate cancer tissue samples from 494 patients, high expression of CD26/DPP4 was associated with poor prognosis, *P* \< 0.001 ([@B20]). Taken all together, the blockage of DPP4 could have resulted in improved survival in prostate cancer patients in our analysis.

There are several potential mechanisms proposed for the role of DPP4i in cancer cells. Immunological function of CD26/DPP4 includes activation of resting T cells, costimulatory effects on T cells and signal transduction leading to increased secretion of cytotoxic granzymes such as TNF-α, IFN-γ, FAS-ligand ([@B1]). Our analyses imply that the anti-tumor activities of DPP4i in solid tumors are unlikely to be solely due to immunologic modulation, as these effects of DPP4i should not be dependent on the expression levels of DPP4 on the organ tissue. Moreover, CD26/DPP4 has a known role in metastasis. CD26 acts as a receptor for plasminogen 2ϵ, which stimulates matrix metalloproteinase-9 (MMP), leading to the degradation of the extracellular matrix required by cells to invade ([@B8], [@B21]). Blocking the DPP4 activity may thus lead to delayed propagation of cancer cells. We also performed various subgroup analyses in patients with prostate cancer (as shown in the results section). While we found an encouraging trend toward the survival benefit favoring the DPP4i cohort, the statistical significance was not reached, likely secondary to small sample size. A study using a larger sample size or prospective trials might help replicate our findings.

Given its role in cancer biology and the results of multiple preclinical studies, the first in human phase I clinical trial was conducted using a humanized antibody to CD26 (YS110) in malignant mesothelioma patients ([@B22]) and reported prolonged disease stabilization with good drug tolerance. One of the side effects with commercially available DPP4i is hypoglycemia, even though less commonly seen compared to sulfonylurea. Interestingly, hypoglycemia was not one of the commonly reported adverse effects in this phase I trial using YS110. Serum DPP4 level can be determined by assays measuring enzymatic cleavage of known DPP4 substrate. The level of inhibition of DPP4 by \>80% that was found in this trial with YS110 was comparable to the oral administration of commercially available DPP4i.

The role of metformin as an anti-tumor agent is well-established in many types of cancer including prostate cancer ([@B23]--[@B25]). Metformin has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent suppression of androgen signaling pathway, and alterations of insulin-like growth factor-1 (IGF-1) signaling pathways that cause the growth and proliferation of prostate cancer. Moreover, metformin increases the number of CD8^+^ tumor-infiltrating lymphocytes and also protects them from apoptosis and exhaustion which is characterized by decreased production of IL-2, TNFα, and IFNγ ([@B26]). Our analysis showed the OS benefit of metformin (HR 0.87) in prostate cancer patients and OS benefit was also evident in metformin and DPP4i combination group (HR 0.80). Further studies should explore if there is any synergistic activity of these two drugs in treatment of prostate cancer. The role of metformin in breast cancer patients is controversial as per published reports so far ([@B27]). Our analysis did show improved OS in breast cancer patients taking metformin (HR 0.81, *P* \< 0.0001) but not in pancreatic cancer patients.

Our analysis has several limitations; mainly that it is a retrospective study which carries its own inherent biases. The sample size was another limitation for subgroup analyses. DPP-4 inhibitors are typically used as a second or third line in those who do not achieve adequate glycemic control to sulfonylurea, metformin, or a thiazolidinedione ([@B28]) leading relatively small sample size. SEER database includes data from 19 different geographical areas covering \~34% of the US population. Therefore, both data and results could be affected by regional trends in diagnosis and treatment of various disease as well as access to health care in those particular geographical areas. And thus caution should be exercised before generalization.

In conclusion, use of CD26/DPP4 inhibitors is associated with improved survival outcomes in patients with prostate cancer but not in breast or pancreatic cancer patients, which may be linked to the protein expression profiling of CD26/DPP4 in these malignancies. A well-designed prospective trial would assist in confirming these findings.
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